Phase I Evaluation of cis-Platinum (II) Diamminedichloride (PDD) and a Combination of PDD Plus Adriamycin
作者： H. J. Wallace , D. J. Higby
DOI: 10.1007/978-3-642-49306-5_13
关键词:
摘要: A phase I clinical trial of cis-platinum (II) diamminedichloride (PDD) was initiated at Roswell Park Memorial Institute in August 1971. The pre-clinical studies this inorganic compound indicated a striking activity several animal tumor models including Dunning ascitic leukemia and Walker 256 carcinosarcoma, Sarcoma 180, DMBA induced mammary tumors female rats [3, 4, 5]. spectrum toxic effects these other suggested the possibility some specificity human cancers. genitourinary tract rats, dogs, monkeys showed evidence severe tissue injury less than lethal doses [1, 2]. Acute tubular necrosis with azotemia marked atrophy prostate gland were seen dogs testicular monkeys. We, therefore, sought patients advanced cancer for inclusion study.
springer.com
sci-hub.st 参考文章(3)
Loretta VanCamp, Barnett Rosenberg, The Successful Regression of Large Solid Sarcoma 180 Tumors by Platinum Compounds Cancer Research. ,vol. 30, pp. 1799- 1802 ,(1970)
S D Sleight, R J Kociba, Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer chemotherapy reports. ,vol. 55, pp. 1- 8 ,(1971)
Rosenberg B, Sleight Sd, Kociba Rj, Inhibition of Dunning asc itic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). Cancer chemotherapy reports. ,vol. 54, pp. 325- ,(1970)